Japanese Paper and Forestry Products Stock News

TSE:4536
TSE:4536Pharmaceuticals

MHRA Approval of Ryjunea® Could Be a Game Changer for Santen Pharmaceutical (TSE:4536)

In the past week, Santen Pharmaceutical announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Ryjunea® (low-dose atropine 0.1 mg/ml) as the first licensed treatment to slow the progression of myopia in children, following earlier European Commission approval and launches in Europe. This milestone offers Santen a new opportunity to address the rising prevalence of childhood myopia in the UK and further strengthens its international presence in paediatric...
TSE:7984
TSE:7984Commercial Services

Kokuyo (TSE:7984): Exploring Valuation After Latest Share Buyback and Stock Split

Kokuyo (TSE:7984) has announced the acquisition of more than 2.7 million shares via a recent buyback on the Tokyo Stock Exchange, following the completion of a stock split and continuing previous buyback activity. See our latest analysis for Kokuyo. Kokuyo’s share price momentum remains strong after the recent buyback, with a year-to-date share price return of 32.04% and a 1-year total shareholder return of 32.59%. That momentum caps off a significant three-year total return of 110% and an...
TSE:3563
TSE:3563Hospitality

Will Food & Life (TSE:3563) Earnings Insights Shape Investor Confidence in Its Long-Term Strategy?

Food & Life Companies recently held its 2025 earnings call on November 7, 2025, providing investors with updates on its financial and operational performance. This regular event serves as a key opportunity for stakeholders to assess the company's progress and reassess expectations going forward. With the earnings call drawing attention, we'll explore how updated financial insights may influence Food & Life Companies’ investment narrative. We've found 16 US stocks that are forecast to pay a...
TSE:2730
TSE:2730Specialty Retail

EDION (TSE:2730) Valuation in Focus After Profits Drop Despite Modest Sales Growth

EDION (TSE:2730) has released its mid-year earnings for September 2025, showing net sales grew 1% compared to last year. However, profits declined across the board. The results highlight ongoing cost pressures affecting overall profitability. See our latest analysis for EDION. Shares of EDION have seen momentum fluctuate over the past year, with investors weighing the solid year-to-date share price return of 10.3% against near-term volatility. The company’s one-year total shareholder return...